On August 1, 2019, The New York Times featured insights by AFAR experts Randall J. Bateman, MD, Tammie L.S. Benzinger, MD, PhD, and David Holtzman, MD, on the potential of blood tests for beta amyloid, the protein most often associated with diagnosing Alzheimer’s disease, and how these tests might help toward earlier diagnoses.
The Times article spotlights their research, originally published in Neurology on August 1, 2019.
Dr. Bateman is a 1997 Glenn/AFAR Scholarships for Research in the Biology of Aging recipient, a 2007 Paul B. Beeson Emerging Leaders Career Development Award in Aging recipient, and a 2015 MetLife Foundation Awards for Medical Research in Alzheimer’s Disease recipient. He is a Charles F. and Joanne Knight Distinguished Professor of Neurology and the Director of the Dominantly Inherited Alzheimer Network Trails Unit at the Washington University School of Medicine in St. Louis.
Dr. Benzinger is a 1997 Glenn/AFAR Scholarships for Research in the Biology of Aging recipient, as well as a Professor of Radiology and Neurological Surgery at the Washington University School of Medicine in St. Louis.
Dr. Holtzman is a 1995 Paul B. Beeson Emerging Leaders Career Development Award in Aging recipient, and a 2006 MetLife Foundation Awards for Medical Research in Alzheimer’s Disease recipient. Dr. Bateman also was the Chair of the Metlife Foundation Awards selection committee. He is also an Andrew B. & Gretchen P. Jones Professor of Neurology at the Hope Center for Neurological Disorders at the Washington University School of Medicine in St. Louis.
Read the article in The New York Times, “A Blood Test for Alzheimer’s? It’s Coming, Scientists Report,” here, and read the original research published in Neurology here.
